THERAPEUTIC PROTEINS AND ORAL VACCINES MARKET ANALYSIS

Market News

Global Therapeutic Proteins and Oral Vaccines Market: Key Developments

• On March 13 2023, Pfizer Inc. and Seagen Inc., a biotechnology company, announced that they had entered into a definitive merger agreement under which Pfizer will acquire Seagen for US$ 229 in cash per Seagen share for a total enterprise value of US$ 43 billion.
• In November 2022, AstraZeneca, a global, science-led biopharmaceutical company, announced an agreement to acquire Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.
• In May 2022, Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced the completion of a US$41 million Series B financing. The financing was led by new investor NexPoint and included participation from existing investors Bristol Myers Squibb, Eshelman Ventures and Kingdon Capital.
• In April 2020, AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine.